Eptifibatide Medi-Market is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. Eptifibatide Medi-Market is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. Eptifibatide Medi-Market is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). Eptifibatide Medi-Market is intended for use with aspirin and heparin.